PEG-rhG-CSF in Patients With Lymphoma Receiving Chemotherapy

The Multi-center,Open-label,Single Arm Clinical Trial of Efficacy and Safety of PEG-rhG-CSF in Patients With Lymphoma Receiving Chemotherapy

Status

Completed

Phases

Phase 4

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT02805218

Enrollment

410

Registered

2016-06-17

Start date

2013-09-30

Completion date

2016-02-29

Last updated

2016-06-20

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Lymphoma

Brief summary

The purpose of this study is to estimate the safety and efficacy of PEG-rhG-CSF in patients with lymphoma receiving chemotherapy.

Interventions

DRUGPEG-rhG-CSF

Study design

Allocation

Intervention model

SINGLE_GROUP

Primary purpose

PREVENTION

Masking

NONE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

* Patients with age ≥ 18 years * diagnosis of lymphoma(Hodgkin's lymphoma and non-Hodgkin's lymphoma) patients * Karnofsky Performance Status Z70 * life expectancy of at least 8 months * normal white blood cell count and platelet count * Written informed consent are acquired

Exclusion criteria

* uncontrolled infection * pregnancy * Have accepted any other anti-tumor drug within 4 weeks before anticipated the study * Other situations that investigators consider as contra-indication for this study

Design outcomes

Primary

Measure	Time frame
The occurrence rate of adverse event	up to 30 days after the patient study completion
The severity of adverse event	up to 30 days after the patient study completion

Secondary

Measure	Time frame
the occurrence rate of grade III/ IV neutropenia during chemotherapy cycles	through the study completion,an average of 5 months

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026